Danazol in treatment of angio‐immunoblastic lymphadenopathy

The clinical manifestations of angio‐immunoblastic lymphadenopathy (AILD) suggest that there is an abnormality in the immune system. Most patients with AILD die from opportunistic infections associated with lymphocyte depletion. As chemotherapy further increases the already high susceptibility of in...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1989-08, Vol.64 (3), p.613-615
Main Authors: Banavali, Shripad D., Parikh, Purvish M., Charak, Bishan Singh, Modi, Alok, Iyer, Rajaraman, Nadkarni, Kanchan S., Saikia, Tapan, Gopal, Ramakrishnan, Soman, Chitralekna S., Advani, Suresh H.
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Danazol - therapeutic use
Female
Humans
Immunoblastic Lymphadenopathy - drug therapy
Immunotherapy
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pregnadienes - therapeutic use
Remission Induction
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The clinical manifestations of angio‐immunoblastic lymphadenopathy (AILD) suggest that there is an abnormality in the immune system. Most patients with AILD die from opportunistic infections associated with lymphocyte depletion. As chemotherapy further increases the already high susceptibility of infections, the therapeutic management of AILD is difficult. The achievement of complete remission (CR) by the patient described here using a danazol‐based regimen raises the hope that treatment of this disease with a noncytotoxic drug may be possible. The rationale behind and advantages of using danazol are discussed.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19890801)64:3<613::AID-CNCR2820640308>3.0.CO;2-K